<DOC>
	<DOC>NCT01363817</DOC>
	<brief_summary>The purpose of this study is to identify a safe and tolerable dose of BMS-906024, either alone or in combination with Dexamethasone in subjects with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma who no longer respond to or have relapsed from standard therapies</brief_summary>
	<brief_title>Study to Evaluate the Safety and Tolerability of Weekly Intravenous (IV) Doses of BMS-906024 in Subjects With Acute T-cell Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma</brief_title>
	<detailed_description>Minimum Age: 10 years and older at selected sites</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Subjects with Tcell acute lymphoblastic leukemia or Tcell lymphoblastic lymphoma refractory to or relapsed from standard therapies Life expectancy of at least 2 months Performance status (PS) 01 (a measure of the ability to carry out activities of daily living); subjects with PS 2 are eligible if due to disease related symptoms Prior anticancer treatment permitted (with specific criteria) Adequate organ function Infection Elevated triglycerides Gastrointestinal disease with increased risk of diarrhea (e.g. inflammatory bowel disease) Unable to tolerate bone marrow biopsy Taking medications known to increase risk of Torsades De Pointes (an abnormal heart rhythm)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>